Meeting
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
Authors
Atsushi Nakamura
Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
Atsushi Nakamura , Ryota Saito , Ryo Ko , Koichi Azuma , Ryo Morita , Makoto Maemondo , Satoshi Oizumi , Kazuhisa Takahashi , Hiroshi Kagamu , Takeshi Isobe , Masahiro Seike , Toshiaki Kikuchi , Isamu Okamoto , Satoshi Morita , Hajime Asahina , Kentaro Tanaka , Kenji Sugio , Kunihiko Kobayashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
jRCTs031180226
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9097)
DOI
10.1200/JCO.2022.40.16_suppl.9097
Abstract #
9097
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2014 ASCO Annual Meeting
NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.
First Author: Akira Inoue
Poster
2023 ASCO Annual Meeting
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
First Author: Fengying Wu